HEMLIBRA 105 MG / 0.7 ML — DIN 02479656
EMICIZUMAB : 105 MG / 0.7 ML · HOFFMANN-LA ROCHE LIMITED · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is HEMLIBRA?
HEMLIBRA 105 MG / 0.7 ML contains EMICIZUMAB : 105 MG / 0.7 ML. It is listed in the Health Canada Drug Product Database under DIN 02479656, held by HOFFMANN-LA ROCHE LIMITED, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 21-Feb-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is HEMLIBRA used for?
Hemlibra® (emicizumab injection) is indicated for hemophilia A (congenital factor VIII deficiency) patients with or without factor VIII inhibitors as routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Emicizumab cost around the world?
Emicizumab is listed on 14 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Czechia | max producer price (ex-factory) | 1 | 6 | CZK███.██ |
| Iceland | max wholesale | 1 | 5 | ISK███.██ |
| Italy | prezzo al pubblico (classe A) | 5 | 5 | EUR███.██ |
| United Arab Emirates | public | 4 | 4 | AED███.██ |
| Austria | KVP (Kassenverkaufspreis) | 4 | 4 | EUR███.██ |
| Bahrain | retail (max) | 1 | 4 | BHD███.██ |
| Greece | producer price (ex-factory) | 4 | 4 | EUR███.██ |
| Hungary | producer price (ex-factory) | 2 | 4 | HUF███.██ |
| Luxembourg | reimbursement | 4 | 4 | EUR███.██ |
| Norway | max AUP (pharmacy retail) | 1 | 4 | NOK███.██ |
| Romania | max producer price | 2 | 4 | RON███.██ |
| Saudi Arabia | public | 2 | 4 | SAR███.██ |
| South Africa | single exit price | 4 | 4 | ZAR███.██ |
| Slovakia | categorised final price | 2 | 3 | EUR███.██ |
59 pack listings across 37 brand entries and 12 price bases, refreshed 07 Sep 2026. Ranges span every Emicizumab pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Emicizumab in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Emicizumab — 6 DINs, of which 6 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| HOFFMANN-LA ROCHE LIMITED | 6 | 6 | HEMLIBRA | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 105 MG / 0.7 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Pack configuration (monograph) | 12 mg/0.4 mL (30 mg/mL), 30 mg/mL, 60 mg/0.4 mL (150 mg/mL), 105 mg/0.7 mL (150 mg/mL), 150 mg/mL, 300 mg/2mL (150 mg/mL) |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Emicizumab |
|---|---|
| ATC code | B02BX06 |
| AHFS class | 20:28.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02479656 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2479656 |
| Brand name | HEMLIBRA |
| Generic / active ingredient | EMICIZUMAB : 105 MG / 0.7 ML |
| Market authorization holder | HOFFMANN-LA ROCHE LIMITED |
| Health Canada schedule | Schedule D |
| ATC code | B02BX06 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B02BX |
| Current status | MARKETED |
| Status date | 21-Feb-2019 |
| Original market date | 2019-02-21 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
6 of 6 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| HEMLIBRA | 30 MG / 1 ML | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | 02479621 |
| HEMLIBRA | 60 MG / 0.4 ML | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | 02479648 |
| HEMLIBRA | 150 MG | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | 02479664 |
| HEMLIBRA | 12 MG / 0.4 ML | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | 02556049 |
| HEMLIBRA | 300 MG / 2 ML | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | 02556057 |
2 · Same class — other molecules in ATC B02BX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Emicizumab | HEMLIBRA | 6 | 6 | Yes |
| Eltrombopag | APO-ELTROMBOPAG · REVOLADE · TEVA-ELTROMBOPAG | 8 | 4 | Yes |
| Fostamatinib | TAVALISSE | 2 | 2 | Yes |
| Romiplostim | NPLATE | 2 | 2 | Yes |
| Avatrombopag | DOPTELET | 1 | 1 | Yes |
| Concizumab | ALHEMO | 4 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B02B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B02BD | Catridecacog · Coagulation Factor Ix · Coagulation Factor Ix, Ii, Vii And X In Comb · Coagulation Factor Viia · Coagulation Factor Viii · +8 more | 216 | 73 |
| B02BC | Combinations · Epinephrine · Local Hemostatics · Thrombin | 23 | 6 |
| B02BA | Phytomenadione | 5 | 2 |
| B02BB | Fibrinogen, Human | 2 | 2 |
4 · Fixed-dose combinations with Canadian supply
| Product | Active ingredients | Holder | Status | DIN |
|---|---|---|---|---|
| ADYNOVATE | ANTIHEMOPHILIC FACTOR (RECOMBINANT), PEGYLATED : 1000 UNIT | TAKEDA CANADA INC | MARKETED | 02498588 |
| ALPROLIX | RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN : 500 UNIT | SANOFI-AVENTIS CANADA INC | MARKETED | 02422913 |
| ALTUVIIIO | *ANTIHEMOPHILIC FACTOR VIII (RECOMBINANT, BDD), FC-VWF-XTEN FUSION PROTEIN : 4000 UNIT | SANOFI-AVENTIS CANADA INC | MARKETED | 02448157 |
| ELOCTATE | ANTIHEMOPHILIC FACTOR (RECOMBINANT BDD), FC FUSION PROTEIN : 500 UNIT | SANOFI-AVENTIS CANADA INC | MARKETED | 02430304 |
| ESPEROCT | ANTIHEMOPHILIC FACTOR VIII (RECOMBINANT, B-DOMAIN TRUNCATED), PEGYLATED : 2000 UNIT | NOVO NORDISK CANADA INC | MARKETED | 02490099 |
| JIVI | ANTIHEMOPHILIC FACTOR (RECOMBINANT, B-DOMAIN DELETED, PEGYLATED) : 1000 UNIT | BAYER INC | MARKETED | 02481774 |
| REBINYN | COAGULATION FACTOR IX (RECOMBINANT), PEGYLATED : 3000 UNIT | NOVO NORDISK CANADA INC | MARKETED | 02532964 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.